<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226783</url>
  </required_header>
  <id_info>
    <org_study_id>D5611C00003</org_study_id>
    <nct_id>NCT02226783</nct_id>
  </id_info>
  <brief_title>D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects</brief_title>
  <official_title>Phase I Study in Healthy Subjects to Evaluate the Pharmacodynamics (PD) of AZD1722 Given With and Without Food (Part A) and a 2-way Crossover to Evaluate the PD of AZD1722 Given as a Free-base Tablet With and Without Omeprazole (Part B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the effect of intake of food in comparison to fasting condition on
      pharmacodynamics of AZD1722 following a twice-daily administration of AZD1722 tablet
      formulation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label, Randomized, Single-center, 3-way Crossover Study in Healthy Subjects
      to Evaluate the Pharmacodynamics Effects of AZD1722 Administered With and Without Food (Part
      A) plus a 2-way Crossover in Subjects to Evaluate the Pharmacodynamic Effect of AZD1722
      Administered as an AZD1722 Free-base Tablet with and without Omeprazole (Part B)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic:- To evaluate the effect of intake of food in comparison to fasting condition on PD of AZD1722 following a twice-daily administration of AZD1722 tablet formulation</measure>
    <time_frame>Stool samples will be collected over 24 hr periods from day -2 to Day 17</time_frame>
    <description>Sodium and phosphorus content in stool collected over 24-hour intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic:- To evaluate the effect of intake of food in comparison to fasting condition on PD of AZD1722 following twice-daily administration of an AZD1722 tablet formulation</measure>
    <time_frame>Stool samples will be collected over 24 hr periods from day -2 to Day 17</time_frame>
    <description>Stool consistency, weight, and frequency measured on a daily basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic:- To evaluate the effect of intake of food in comparison to fasting condition on PD ofAZD1722 following twice-daily administration of an AZD1722 tablet formulation</measure>
    <time_frame>Urine will be collected in 24 hour intervals from Day -2 to Day 17</time_frame>
    <description>Urinary sodium and phosphorus content over 24-hour intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: To evaluate the plasma concentrations of AZD1722</measure>
    <time_frame>Predose, 1, 2, and 4 hours post morning dose for measurement of AZD1722 in plasma will be taken on days 1, 4, 7, 10, 13, and 16</time_frame>
    <description>AZD1722 plasma concentrations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety:- To evaluate the safety of AZD1722</measure>
    <time_frame>Safety assessments will be performed throughout the study from Baseline to final follow-up visit (Day-2 to Day 26)</time_frame>
    <description>Adverse events, vital signs, physical examinations, ECGs, and laboratory assessments (chemistry, hematology, and urinalysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory:-To evaluate the effect of high and low gastric pH on the PD of AZD1722 following twice daily administration of an AZD1722 free-base tablet formulation given with and without omeprazole</measure>
    <time_frame>Stool and urine samples will be collected over 24 hr periods from day -2 to Day 14</time_frame>
    <description>Stool sodium and phosphorus content; stool frequency, weight, and consistency; and urine sodium and phosphorus content assessed over 24-hour intervals</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy Volunteers Food Interaction Study</condition>
  <arm_group>
    <arm_group_label>Treatment A AZD1722 salt tablet (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B AZD1722 salt tablet (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C AZD1722 salt tablet (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat D AZD1722 free-base tablet (fast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat E AZD1722 free-base+Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722 salt tablet</intervention_name>
    <description>AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).</description>
    <arm_group_label>Treatment A AZD1722 salt tablet (fasted)</arm_group_label>
    <arm_group_label>Treatment B AZD1722 salt tablet (fed)</arm_group_label>
    <arm_group_label>Treatment C AZD1722 salt tablet (fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722 free base tablet</intervention_name>
    <description>AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).</description>
    <arm_group_label>Treat D AZD1722 free-base tablet (fast)</arm_group_label>
    <arm_group_label>Treat E AZD1722 free-base+Omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722 free base tablet + Omeprazole</intervention_name>
    <description>AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722</description>
    <arm_group_label>Treat E AZD1722 free-base+Omeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female volunteers aged 18 to 65 years

          2. Females of childbearing potential had to have a negative pregnancy test and females of
             childbearing potential included in the study had to use 2 effective methods of
             avoiding pregnancy, females of nonchildbearing potential to fulfill 1 of the following
             criteria:

               1. Postmenopausal, defined as amenorrhea for at least 12 months or more following
                  cessation of all exogenous hormonal treatment and luteinizing hormone (LH) and
                  follicle-stimulating hormone (FSH) levels in the postmenopausal range

               2. Documentation of irreversible surgical sterilization by hysterectomy, tubal
                  occlusion, bilateral oophorectomy, or bilateral salpingectomy but not tubal
                  ligation

          3. Had a body mass index (BMI) of 18 and 30 kg/m2, inclusive, and weight at least 50 kg
             and no more than 100 kg

          4. Regular bowel habits of at least 1 stool portion per day.

        Exclusion Criteria:

        (1) History of clinically-significant disease or disorder (2) History or presence of GI,
        hepatic, or renal disease, including GI surgery, or any condition known to interfere with
        absorption, distribution, metabolism, or excretion of drugs. (3) Any clinically significant
        illness, medical/surgical procedure, or trauma within 4 weeks (4) any
        clinically-significant abnormalities in clinical chemistry, hematology, or urinalysis.

        (5) Abnormal vital signs after a 10-minute supine rest, any clinically-significant
        abnormalities in rhythm, conduction, or morphology of resting ECG (6) Prolonged QTcF
        greater than 450 ms or shortened QTcF less than 340 ms or family history of long QT
        syndrome.

        (7) Loose stools (Bristol Stool Form Score [BSFS] of 6 or 7) 2 or more days during the 7
        days prior to randomization (8) Use of medications that are known to affect stool
        consistency and/or GI motility, including fiber supplements, probiotic supplements,
        probiotic supplements in medication form, antidiarrheals, prokinetic drugs, enemas,
        probiotic medications or supplements (ie, Activia®); or salt or electrolyte supplements
        containing sodium, potassium, chloride, or bicarbonate formulations during the past 7 days
        before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase I Services, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>KS 66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>PK</keyword>
  <keyword>PD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

